VJHemOnc is committed to improving our service to you

EHA 2019 | TRANSCEND CLL-004 update from EHA: liso-cel for R/R CLL

VJHemOnc is committed to improving our service to you

William Wierda

William Wierda, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, explains the update on the TRANSCEND CLL-004 trial (NCT03331198) of lisocabtagene maraleucel at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter